Should I provide an anti-platelet agent to a patient with secondary thrombocytosis?

Antiplatelet therapy is not recommended, even in patients with extreme thrombosis, due to lack of evidence for thrombotic risk and theoretical risk of paradoxical bleeding from acquired von Willebrand syndrome. In cases where thrombosis has been reported in patients with reactive thrombocytosis, it is not known whether elevated platelet counts are causal or simply a marker of underlying disease with high thrombotic risk. Learn more here.